<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00304135</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000470411</org_study_id>
    <secondary_id>FFCD-9902</secondary_id>
    <secondary_id>SANOFI-FFCD-9902</secondary_id>
    <secondary_id>LILLY-FFCD-9902</secondary_id>
    <secondary_id>FFCD-FNCLCC-SFRO-9902</secondary_id>
    <nct_id>NCT00304135</nct_id>
  </id_info>
  <brief_title>Fluorouracil, Cisplatin, and Radiation Therapy or Gemcitabine and Oxaliplatin in Treating Patients With Nonmetastatic Biliary Tract Cancer That Cannot Be Removed By Surgery</brief_title>
  <official_title>Randomized Phase II-III Study of Chemoradiation With Fluorouracil and Cisplatin Versus Chemotherapy (Gemcitabine/Oxaliplatin) in Non Resectable But Non Metastatic Cancer of the Biliary Tract</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federation Francophone de Cancerologie Digestive</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federation Francophone de Cancerologie Digestive</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as fluorouracil, cisplatin, oxaliplatin, and&#xD;
      gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the&#xD;
      cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy)&#xD;
      may kill more tumor cells. Radiation therapy uses high-energy x-rays to kill tumor cells. It&#xD;
      is not yet known whether giving fluorouracil and cisplatin together with radiation therapy is&#xD;
      more effective than giving gemcitabine together with oxaliplatin in treating nonmetastatic&#xD;
      biliary tract cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase II/III trial is studying fluorouracil, cisplatin, and&#xD;
      radiation therapy to see how well they work compared to gemcitabine and oxaliplatin in&#xD;
      treating patients with nonmetastatic biliary tract cancer that cannot be removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare the 3-month progression rate in patients with unresectable, nonmetastatic cancer&#xD;
           of the biliary tract treated with fluorouracil, cisplatin, and radiotherapy vs&#xD;
           gemcitabine hydrochloride and oxaliplatin. (phase II)&#xD;
&#xD;
        -  Compare the overall survival of patients treated with these regimens. (phase III)&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare toxicities of these regimens in these patients. (phase II)&#xD;
&#xD;
        -  Compare the quality of life at initial drainage (phase II) and overall (phase III) of&#xD;
           patients treated with these regimens.&#xD;
&#xD;
        -  Compare the biliary complication rate in patients treated with these regimens.&#xD;
&#xD;
        -  Compare the duration of hospitalization of patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to&#xD;
      disease location (gallbladder vs intrahepatic biliary duct vs extrahepatic biliary duct).&#xD;
      Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients undergo radiotherapy once daily, 5 days a week on days 1-33. Patients&#xD;
           also receive fluorouracil IV continuously over 5 days once a week in weeks 1-5 and&#xD;
           cisplatin IV over 15 minutes on days 1-4 and 29-32 (or days 1 or 2 and 29 or 30) in the&#xD;
           absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Arm II: Patients receive gemcitabine hydrochloride IV over 100 minutes and oxaliplatin&#xD;
           IV over 2 hours on day 1. Treatment repeats every 14 days for up to 12 courses in the&#xD;
           absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Quality of life is assessed at baseline and then every 3 months thereafter.&#xD;
&#xD;
      After completion of study therapy, patients are followed periodically for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 170 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression rate at 3 months</measure>
    <time_frame>2012</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2012</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biliary complication rate</measure>
    <time_frame>2012</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Extrahepatic Bile Duct Cancer</condition>
  <condition>Gallbladder Cancer</condition>
  <condition>Liver Cancer</condition>
  <arm_group>
    <arm_group_label>Radio-chimiothérapie</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radio-chimiothérapie</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GEMOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GEMOX</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <arm_group_label>Radio-chimiothérapie</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <arm_group_label>GEMOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <arm_group_label>GEMOX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of cancer of the biliary tract by 1 of the following methods:&#xD;
&#xD;
               -  Histologic confirmation&#xD;
&#xD;
               -  Stenosis of the biliary tract by MRI, CT scan, or ECHO&#xD;
&#xD;
          -  Unresectable disease&#xD;
&#xD;
          -  Amenable to radiotherapy&#xD;
&#xD;
          -  No visceral metastases by imaging&#xD;
&#xD;
               -  Hepatic adenopathies that can be included in a radiation field allowed&#xD;
&#xD;
          -  No known ampulla of Vater or pancreatic cancer involving the biliary tract&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  WHO performance status 0-2&#xD;
&#xD;
          -  Creatinine &lt; 1.5 mg/dL&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 75,000/mm^3&#xD;
&#xD;
          -  Prothrombin time &gt; 70%&#xD;
&#xD;
          -  Bilirubin ≤ 2.9 mg/dL (after hepatic draining, if needed)&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
          -  No symptomatic cardiac insufficiency&#xD;
&#xD;
          -  No other comorbidity that would preclude study therapy&#xD;
&#xD;
          -  No other prior malignancy except basal cell skin cancer or carcinoma in situ of the&#xD;
             cervix&#xD;
&#xD;
          -  No prior hydatid cyst or alveolar echinococciasis&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No recent biliary surgery&#xD;
&#xD;
          -  No hepatic intra-arterial chemotherapy&#xD;
&#xD;
          -  No prior anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno Chauffert</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Georges Francois Leclerc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier General</name>
      <address>
        <city>Belfort</city>
        <zip>90000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Pierre Oudot</name>
      <address>
        <city>Bourgoin-Jallieu</city>
        <zip>38300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Louis Pasteur</name>
      <address>
        <city>Colmar</city>
        <zip>68024</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Dax</name>
      <address>
        <city>Dax</city>
        <zip>40100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Du Bocage</name>
      <address>
        <city>Dijon</city>
        <zip>21034</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Lutte Contre le Cancer Georges-Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Departemental</name>
      <address>
        <city>La Roche Sur Yon</city>
        <zip>F-85025</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C. H. Du Mans</name>
      <address>
        <city>Le Mans</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier General de Mont de Marsan</name>
      <address>
        <city>Mont-de-Marsan</city>
        <zip>40000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR D'Orleans - Hopital de la Source</name>
      <address>
        <city>Orleans</city>
        <zip>45100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Bichat - Claude Bernard</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Pitie-Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Sebastopol, C.H.U. de Reims</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35062</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Semur en Auxois</name>
      <address>
        <city>Semur en Auxois</city>
        <zip>21140</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Universitaire Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Tarbes</name>
      <address>
        <city>Tarbes</city>
        <zip>65013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Phelip JM, Vendrely V, Rostain F, Subtil F, Jouve JL, Gasmi M, Michel P, Le Malicot K, Smith D, Seitz JF, Fauchart JP, Martin P, Bennouna J, Morin T, Bonnet I, Maingon P, Lepage C, Chauffert B. Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Fédération Francophone de Cancérologie Digestive 9902 phase II randomised study. Eur J Cancer. 2014 Nov;50(17):2975-82. doi: 10.1016/j.ejca.2014.08.013. Epub 2014 Sep 17.</citation>
    <PMID>25241229</PMID>
  </results_reference>
  <verification_date>December 2006</verification_date>
  <study_first_submitted>March 15, 2006</study_first_submitted>
  <study_first_submitted_qc>March 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2006</study_first_posted>
  <last_update_submitted>May 27, 2016</last_update_submitted>
  <last_update_submitted_qc>May 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>localized unresectable adult primary liver cancer</keyword>
  <keyword>unresectable extrahepatic bile duct cancer</keyword>
  <keyword>unresectable gallbladder cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Gallbladder Neoplasms</mesh_term>
    <mesh_term>Bile Duct Neoplasms</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

